Jaguar Health Declares Series O Preferred Dividend for March 2 Record Date
Jaguar Health’s board declared a one-time dividend of Series O convertible preferred stock to shareholders and warrant holders of record on March 2, 2026, payable March 4, to provide dilution protection during debt restructuring. Jaguar advances crofelemer for microvillus inclusion disease, targeting Breakthrough Therapy and NDA filing in H1 2027.
1. Special Stock Dividend Details
Jaguar Health’s Board declared a one-time special stock dividend of Series O convertible preferred shares to holders of common stock and certain warrants as of the March 2, 2026 record date, with payment scheduled for March 4, 2026.
2. Conversion Terms and Timeline
Each preferred share converts into common stock at market value at the board’s election any time before December 31, 2026, after which conversion occurs automatically on that date.
3. Strategic Rationale and Debt Restructure
The dividend is intended to reward shareholders and provide protection against dilution as Jaguar explores pathways to repay and restructure its existing indebtedness.
4. Crofelemer Development Progress
Jaguar is advancing its crofelemer oral formulation for microvillus inclusion disease, having demonstrated a 37% reduction in parenteral support in an initial pediatric patient, and is targeting Breakthrough Therapy designation with an NDA filing in H1 2027.